Phaseline

Companies › Alpha-9 Oncology USA

Alpha-9 Oncology USA: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[177Lu]Lu-A9-0631
Lutetium-177 labeled GRPR-targeting peptide
GRPRPhase 1Breast CancerDec 2028
[225Ac]Ac-A9-0642
Actinium-225 labeled GRPR-targeting peptide
GRPRPhase 1Breast CancerDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07661641[177Lu]Lu-A9-0631Phase 1Breast CancerOncologyDec 2028
NCT07661641[225Ac]Ac-A9-0642Phase 1Breast CancerOncologyDec 2028

Targets

GRPR (2)

Companies with the same targets

Novartis Orano Med Theranostics, SAS Eli Lilly

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.